![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
D Scherman and JP Henry
[3H]Reserpine bound reversibly in vitro to chromaffin granule membranes. Binding was temperature-dependent and slow, and had biphasic kinetics. The addition of ATP accelerated the kinetics, which became monophasic and comparable to those of [3H] dihydrotetrabenazine, without affecting the binding equilibrium constants. The ATP effect was related to H+ -electrochemical gradient generation by the granule membrane H+ pump. Binding of reserpine to chromaffin granule membranes occurred on two classes of sites: R1, Bmax = 7 pmoles/mg of protein and KD = 0.7 nM, and R2, Bmax = 60 pmoles/mg of protein and KD = 25 nM. Sites R2 were considered to be equivalent to [3H] dihydrotetrabenazine binding sites, as the densities of the R2 and the [3H] dihydrotetrabenazine binding sites were similar and because tetrabenazine displaced reserpine from R2 sites. Sites R1 were tetrabenazine-resistant; they were involved in monoamine uptake, since their KD values were similar to the KI values of reserpine for noradrenaline uptake. Sites R1 were less abundant than sites R2 on chromaffin granule membranes, but they were present at the same concentration in intact chromaffin granules. We propose that the monoamine carrier exists in two forms: (a) an active form bearing both high- and low-affinity sites for reserpine and (b) an inactive form with only the low-affinity R2 sites.
This article has been cited by other articles:
|
|
 |
|
  Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial Neurology, February 14, 2006; 66(3): 366 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. PARSONS Transport mechanisms in acetylcholine and monoamine storage FASEB J, December 1, 2000; 14(15): 2423 - 2434. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. L. Colliver, S. J. Pyott, M. Achalabun, and A. G. Ewing VMAT-Mediated Changes in Quantal Size and Vesicular Volume J. Neurosci., July 15, 2000; 20(14): 5276 - 5282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Mundorf, K. P. Troyer, S. E. Hochstetler, J. A. Near, and R. M. Wightman Vesicular Ca2+ Participates in the Catalysis of Exocytosis J. Biol. Chem., March 24, 2000; 275(13): 9136 - 9142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. E. Smith and R. Levi LLC-PK1 Cells Stably Expressing the Human Norepinephrine Transporter: A Functional Model of Carrier-Mediated Norepinephrine Release in Protracted Myocardial Ischemia J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 456 - 463. [Abstract] [Full Text]
|
|
|
|
|
|
M. K. Sievert and A. E. Ruoho Peptide Mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-Iodo-4'-azidophenyl)propionyl]tetrabenazine Binding Sites for the Synaptic Vesicle Monoamine Transporter J. Biol. Chem., October 10, 1997; 272(41): 26049 - 26055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Finn III and R. H. Edwards Individual Residues Contribute to Multiple Differences in Ligand Recognition between Vesicular Monoamine Transporters 1 and 2 J. Biol. Chem., June 27, 1997; 272(26): 16301 - 16307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Krantz, D. Peter, Y. Liu, and R. H. Edwards Phosphorylation of a Vesicular Monoamine Transporter by Casein Kinase II J. Biol. Chem., March 7, 1997; 272(10): 6752 - 6759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Merickel, H. R. Kaback, and R. H. Edwards Charged Residues in Transmembrane Domains II and XI of a Vesicular Monoamine Transporter Form a Charge Pair That Promotes High Affinity Substrate Recognition J. Biol. Chem., February 28, 1997; 272(9): 5403 - 5408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Steiner-Mordoch, A. Shirvan, and S. Schuldiner Modification of the pH Profile and Tetrabenazine Sensitivity of Rat VMAT1 by Replacement of Aspartate 404 with Glutamate J. Biol. Chem., May 31, 1996; 271(22): 13048 - 13054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Peter, T. Vu, and R. H. Edwards Chimeric Vesicular Monoamine Transporters Identify Structural Domains That Influence Substrate Affinity and Sensitivity to Tetrabenazine J. Biol. Chem., February 9, 1996; 271(6): 2979 - 2986. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
